CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Renin-angiotensin system inhibitorsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1284 Hydroxychloroquine Wiki 0.10

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Switch or Maintenance of Renin-Angiotensin System Inhibitors in Patients With Covid-19: A Randomized Proof of Concept Trial

The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.

NCT04493359 Covid19 Angiotensin II Receptor Antagonist Adverse Reaction Drug: Renin-angiotensin system inhibitors

Primary Outcomes

Description: Combined of need for ICU or mortality

Measure: Need for ICU or mortality

Time: 30 days

Secondary Outcomes

Description: Evaluate correlation between hs-TnT and covid-19 severity

Measure: High sensitivity troponin levels and covid-19 severity

Time: 30 days

Description: Evaluate correlation of ACE-2 activity and disease severity

Measure: ACE-2 activity and disease severity

Time: 30 days

Description: Evaluate correlation of ACE-2 activity and Renin-angiotensin system inhibitors

Measure: ACE-2 activity with different Renin-angiotensin system inhibitors

Time: 30 days

Description: Evaluate blood pressure control and acute renal failure in each arm (safety)

Measure: Blood control and acute renal failure

Time: 30 days


No related HPO nodes (Using clinical trials)